Context Therapeutics Inc. (CNTX) Stock Price & Analysis
Context Therapeutics Inc. (CNTX) rose 3.68% to USD 0.61 as of July 25, 2026 at 07:39 UTC, according to Nexqual real-time market data.
CNTX last closed at USD 0.59; the session ranged USD 0.56–0.63 on volume of 2,045,343 shares. Market capitalization is $56.42M, with a 52-week range of USD 0.55–3.62 (NCM). Source: Nexqual, July 25, 2026 at 07:39 UTC.
Key Statistics (as of July 25, 2026 at 07:39 UTC)
| Price | USD 0.61 |
|---|---|
| Change | ▲ 3.68% (up) |
| Previous Close | USD 0.59 |
| Open | USD 0.61 |
| Day Range | USD 0.56 – 0.63 |
| 52-Week Range | USD 0.55 – 3.62 |
| Volume | 2,045,343 shares |
| Market Cap | $56.42M |
| Exchange | NCM |
Technical Analysis (CNTX)
Nexqual's technical model rates CNTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 25.9 (oversold) |
| vs SMA50 | Below (USD 1.31) |
| MACD | -0.16 (negative) |
Analyst Ratings (CNTX)
Wall Street analysts rate CNTX "None" based on 8 analysts, with a mean price target of USD 5.38 (range USD 4–7), per Nexqual as of July 25, 2026 at 07:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 5.38 |
| High Target | USD 7 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 10 / 0 / 0 |
Earnings (CNTX)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-12-31 | USD -0.14 vs est -0.11 ▼ miss |
| 2025-09-30 | USD -0.1 vs est -0.09 ▼ miss |
| 2025-06-30 | USD -0.09 vs est -0.05 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:39 UTC.
Financials & Fundamentals (CNTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -56.19% |
| Debt / Equity | 0.54 |
| Current Ratio | 8.96 |
| Total Cash | $54.53M |
| Total Debt | $282,424 |
| Free Cash Flow | $-23.80M |
Source: Nexqual, July 25, 2026 at 07:39 UTC.
Financial Health Score (CNTX)
Nexqual rates Context Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $55M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$33M |
| Efficiency | Critical — ROE -56%, ROA -35.8% |
Ownership (CNTX)
| Insider Ownership | +1.35% |
|---|---|
| Institutional Ownership | +82.16% |
| Shares Outstanding | 91.88M |
| Float | 42.82M |
| Short % of Float | +8.32% |
Source: Nexqual, July 25, 2026 at 07:39 UTC.
Leadership (CNTX)
Context Therapeutics Inc. is led by Martin A. Lehr (age 41), Co-Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 07:39 UTC.
| Co-Founder, President, CEO & Director | Martin A. Lehr (age 41) |
|---|---|
| CFO & Treasurer | Jennifer Minai-Azary (age 47) |
| Senior Vice President of Operations | Christopher Beck |
| Associate Director of Accounting | Jeffrey Liebman |
| Senior Vice President of Technical Operations | Jennifer Dashnau |
Major Backers & Investors (CNTX)
Notable institutional backers of Context Therapeutics Inc. include MPM Bioimpact LLC, Deep Track Capital, Lp, Nextech Invest, Ltd., according to Nexqual as of July 25, 2026 at 07:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MPM Bioimpact LLC | 11.62% |
| Deep Track Capital, Lp | 8.08% |
| Nextech Invest, Ltd. | 8.08% |
| Soleus Capital Management, L.P. | 7.58% |
| Octagon Capital Advisors LP | 5.71% |
| Blue Owl Capital Holdings LP | 5.54% |
| Avidity Partners Management, LP | 5.44% |
| Franklin Resources, Inc. | 4.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.48% |
Source: Nexqual, July 25, 2026 at 07:39 UTC.
From Context Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors.
- The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRAI | Marpai, Inc. | USD 2.37 | ▲ 26.74% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| DATS | DatChat, Inc. | USD 2.66 | ▲ 16.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:39 UTC. This page is informational and not investment advice.